Scope, Claims, and US Patent Landscape for US Patent 9,265,720 (Sublingual Zolpidem Tablet Using Carrier Particles + Mucoadhesion Promoter)
US Patent 9,265,720 covers a tightly defined method of treating insomnia (and “sleep on demand”) using a sublingual tablet whose design is driven by microstructured presentation: zolpidem (or hemitartrate) microparticles placed on larger carrier particles with mucoadhesion-promoting-agent microparticles also presented on the carrier exterior, with performance requirements tied to rapid measurable plasma exposure and sleep maintenance after sublingual dosing. The claim set is layered so that broad infringement can be defeated by changing (1) the dosing route/dosage form, (2) the carrier particle presentation architecture, or (3) the PK/PD performance targets.
What does US Patent 9,265,720 claim and what is the core invention?
Featured-snippet answer: The patent claims a sublingual administration method using a tablet made from carrier particles bearing zolpidem microparticles and mucoadhesion-promoter microparticles on the carrier exterior, with measured PK timing targets (measurable plasma within 10 minutes, Tmax shift range ~80 to 160 minutes) and sleep maintenance for at least ~6 hours.
Claim 1 (independent) is a performance + architecture claim
Claim 1 defines infringement by a combination of:
-
Route and dosage form
- “Sublingually administering” the composition
- “Tablet sized for placement under a tongue” (not buccal, not oral swallow, not oral disintegrating without sublingual placement)
-
Particle architecture (structural/compositional constraints)
- Carrier particles with exterior surfaces
- Zolpidem (or pharmaceutically acceptable salt) particles sized smaller than carrier
- Zolpidem particles are presented at least in part on the exterior surfaces
- Zolpidem particles cover at least 90% of the exterior surfaces of carrier particles
- Mucoadhesion promoting agent particles are sized smaller than carrier
- Mucoadhesion agent particles are also presented at least in part on the exterior surfaces
- Zolpidem particles and mucoadhesion particles are both on the carrier exterior (co-location requirement)
-
PK/time performance targets (functional targets)
- (i) Measurable plasma concentration within 10 minutes
- (ii) A time difference between first measurable plasma concentration and Cmax (Tmax window) between about 80 and 160 minutes
- (iii) A plasma concentration “capable of maintaining sleep” for at least about 6 hours after sublingual administration
-
Therapeutic outcome linkage
- The method “thereby” treats insomnia.
Claim 3 is essentially the same structure with a different therapeutic framing (“sleep on demand”), so claim coverage is driven more by the composition architecture + route + PK/sleep maintenance than by the named indication label.
Dependent claims tighten the scope without expanding it materially
Dependent claims add narrower constraints on:
- Insomnia subtypes (claim 2)
- Release profile in USP paddle phosphate buffer pH 6.8 (claims 4-5)
- Alertness/psychomotor impairment at 7+ hours (claim 6)
- Specific zolpidem salt (claim 7)
- Particle typology and size (claims 8-9)
- Zolpidem weight percent (claim 10)
- Dose unit mass range (claim 11)
- Mucoadhesion agent identity and crosslinking (claims 12-13)
- Mucoadhesion agent loading (claim 14)
- Excipients: binder/disintegrant identity and loading (claims 15-18)
- Carrier particle mean diameter (claim 19)
- Carrier material identity (mannitol and spray dried) (claims 20-21)
- Carrier loading range (claim 22)
- Coverage metric range (claim 23)
- Lubricant identity (claim 25)
- Tablet physical size/mass (claim 26)
These dependent claims mostly create fallback positions for validity and provide granular infringement targets for litigation discovery and expert analysis.
How broad is the coverage, claim-by-claim, and what design-arounds work?
Featured-snippet answer: Coverage is broad at the top level across zolpidem salts and mucoadhesion agents, but narrowed by a strict co-presented carrier exterior architecture (zolpidem and mucoadhesion particles must both be on carrier exterior with ≥90% zolpidem surface coverage) plus substantially specific PK and sleep maintenance outcomes.
Route/design-around: leaving the sublingual tablet paradigm
- If a competitor uses buccal, transmucosal spray, film, oral swallow, or intranasal delivery, claim 1’s “tablet sized for placement under a tongue” and “sublingually administering” limitation is directly attacked.
- Even if PK is similar, lack of route/dosage form is a clean noninfringement path.
Architecture/design-around: altering “≥90% exterior coverage” or co-presentation
Claim 1 requires:
- Zolpidem particles cover at least 90% of carrier exterior surfaces, and
- Mucoadhesion agent particles are also present on the exterior.
Potential noninfringement strategies (in practical claim construction terms):
- Lower zolpidem surface coverage below 90%
- Move mucoadhesion agent away from exterior presentation (example: located internally, separated, or preformed in a way that does not meet “presented… upon the exterior surfaces”)
- Use a formulation where zolpidem is not microparticles smaller than the carrier (if zolpidem particles are comparable size or larger, literal limitations may fail)
Architecture/design-around: changing particle size relationships
Even without changing the “exterior presentation” concept, dependent claims create additional barriers:
- Microparticle designation (claim 8) and mean diameter 1-10 µm (claim 9)
- Carrier mean diameter 150-400 µm (claim 19)
If infringement on claim 1 is contested, these dependent limits help define what “counts” as the claimed architecture in prosecution history and expert reconstruction, but they do not narrow claim 1 directly unless litigants pivot to dependent claim coverage.
Functional/design-around: missing the PK timing and 6-hour sleep maintenance targets
Claim 1 includes PK/therapeutic outcome targets tied to measured plasma profiles:
- Measurable within 10 minutes
- Difference between first measurable concentration and Cmax between 80-160 minutes
- Sleep maintenance for at least 6 hours
Even if the particle architecture is similar, a competitor that shows a different measurable timing, different first measurable-to-Cmax window, or different sleep maintenance may avoid meeting claim 1 as a whole (especially if those are construed as required therapeutic outcome limitations rather than mere aspirational targets).
Dependent claim 6 adds another functional defense point:
- Plasma concentration does not cause decreased alertness/impairment at least 7 hours after sublingual administration.
Release profile/design-around
Claims 4-5 require at least 50% release within:
- 5 minutes (claim 4) and optionally
- 3 minutes (claim 5)
in USP paddle apparatus with phosphate buffer pH 6.8.
A competitor can try to design slower-release formulations that still meet PK targets but fail the strict in vitro release thresholds, depending on how the claims are litigated and construed.
What specific formulation elements are the strongest “infringement hooks”?
Featured-snippet answer: The most litigated and easiest to test are (1) the particle presentation architecture (zolpidem and mucoadhesion agent both presented on carrier exterior; zolpidem covers ≥90% of exterior), (2) the PK timing targets (measurable within 10 minutes; first measurable-to-Cmax window 80-160 minutes), and (3) the “sleep maintenance for ≥6 hours” outcome.
Highest leverage limitations
-
Co-presentation requirement
- Both zolpidem and mucoadhesion promoter particles are “presented… upon the exterior surfaces” of the carrier particles.
-
Zolpidem exterior coverage threshold
- Zolpidem particles cover “at least 90%” of the carrier exterior surfaces.
-
Measured PK timing
- A measurable plasma concentration within 10 minutes (fast onset)
- A specific time difference between first measurable concentration and Cmax (delayed peak relative to first detection)
-
Sleep maintenance
- “Plasma concentration capable of maintaining sleep for at least about 6 hours.”
Strong secondary hooks (dependent claims)
- Zolpidem salt identity (hemitartrate, claim 7)
- Mucoadhesion agent identity (sodium carboxymethylcellulose, claim 12; croscarmellose sodium, claim 13)
- Dosing ranges (claims 10-11; tablet size/mass claim 26)
- Excipients (microcrystalline cellulose or silicified form and binder/disintegrant loading ranges)
- Coverage metric range (claim 23: coverage 130%-180%)
- USP paddle dissolution release within 3-5 minutes (claims 4-5)
These dependent hooks can become decisive in narrowing to a particular competitor product profile.
How does US 9,265,720 fit into the broader US zolpidem IP landscape?
Featured-snippet answer: The patent targets a specific delivery mechanism for zolpidem: a sublingual tablet with carrier-surface microstructured placement designed to reach measurable plasma quickly and support sleep maintenance. In the broader zolpidem landscape, competitors typically face layered IP across (a) zolpidem polymorph/salt selection, (b) sublingual/buccal delivery systems, (c) rapid dissolution/disintegration performance, and (d) mucoadhesive polymer use. US 9,265,720 is most likely positioned against sublingual “first-in-human PK” and rapid onset tablet architectures.
Likely adjacency categories that overlap with this patent’s claimed subject matter
- Dosage form and route IP
- Sublingual tablets, wafer/film systems, fast dissolving sublingual formats.
- Mucoadhesive polymer IP
- CMC/croscarmellose sodium, other swelling polymers designed to remain at mucosa long enough to sustain drug exposure.
- Particle engineering IP
- Carrier particles with drug and excipient presented on exterior surfaces, micro/macro particle ratios, and surface coverage metrics.
- PK-anchored “performance” claims
- Claims that tie structure to specific plasma time relationships and sleep endpoints, which increases infringement complexity but also increases “design around” difficulty if competitors chase the same PK targets.
When does US 9,265,720 lose exclusivity, and how do you forecast launch risk?
Featured-snippet answer: Exclusivity and enforceable period depend on the patent’s prosecution history and any FDA-related patent term adjustments or restorations. Without those fields, the only actionable forecast available from the claim text alone is that the patent will continue to be a blocking IP risk until it expires or is invalidated, and the claim architecture suggests it is intended to cover a specific commercial product profile.
Practical litigation forecast for this claim structure
For Paragraph IV-type challenges (small molecule) or generic product development:
- The most likely infringement theories are literal infringement on the particle architecture and PK outcomes, supported by dissolution testing (claims 4-5) and tablet manufacturing characterization (particle size and surface coverage).
- The most likely defenses are:
- Non-sublingual route/dosage form
- Failure of ≥90% exterior zolpidem coverage
- Different mucoadhesion agent presentation (not co-presented on exterior)
- Different PK/time relationships or lack of ≥6-hour sleep maintenance
- Different dissolution release profile in USP paddle conditions
What would an infringement analysis focus on for US 9,265,720?
Featured-snippet answer: Test and evidence should be structured around (1) particle-engineering characterization (surface coverage, particle size distributions, and localization of zolpidem and mucoadhesion agent), (2) in vitro dissolution release in USP paddle phosphate buffer pH 6.8, and (3) in vivo plasma PK sampling with defined “first measurable” detection and Cmax timing.
Evidence plan mapped to claim elements
- Particle characterization
- Determine carrier mean diameter (dependent claim 19) and presence of drug/mucoadhesion microparticles on carrier exterior.
- Quantify zolpidem surface coverage on carrier exterior surfaces (≥90% threshold in claim 1; coverage 130%-180% in claim 23).
- Dissolution release testing
- USP paddle dissolution in phosphate buffer pH 6.8.
- Measure % zolpidem release at 3 and 5 minutes (claims 4-5).
- PK sampling
- Ensure plasma is measured with sufficient resolution to establish:
- first measurable within 10 minutes
- time difference from first measurable to Cmax within 80-160 minutes
- exposure sufficient for sleep maintenance at ≥6 hours
- Clinical/PD endpoints
- Sleep maintenance duration and alertness/psychomotor impairment at ≥7 hours (claim 6 if asserted).
How strong is the patent estate around this specific claim?
Featured-snippet answer: Based on the claim set alone, the patent is strong on product-specific delivery-system architecture plus PK outcome performance. The breadth is constrained, which can help validity against prior art but can also increase infringement complexity. Enforcement will likely hinge on expert reconstructions of particle surface presentation and PK endpoint compliance.
Claim strategy signals from the dependent set
The dependent claims show a prosecution strategy that:
- Anchors the concept in sublingual delivery
- Locks in specific particle and mucoadhesive polymer options
- Adds quantitative dissolution and coverage metrics
- Adds PK and behavioral outcomes that can be directly tested in product studies
This combination is designed to be harder to “design around” without changing the underlying delivery mechanism and/or the performance profile.
Key Takeaways
- US 9,265,720 covers sublingual zolpidem treatment using a tablet made from carrier particles whose exterior surfaces host both zolpidem microparticles and mucoadhesion-promoting-agent microparticles, with zolpidem covering ≥90% of carrier exterior surfaces.
- The method is not only structural; it is performance-tethered to measurable plasma within 10 minutes, a defined first-measurable-to-Cmax window of ~80 to 160 minutes, and sleep maintenance for at least ~6 hours.
- The most actionable noninfringement levers are:
- change route/dosage form away from sublingual tongue placement tablets
- reduce zolpidem exterior surface coverage below 90%
- separate mucoadhesion agent from the carrier exterior presentation
- shift PK timing outside the specified windows and/or fail sleep maintenance threshold
- Dependent claims add hard rails: fast USP paddle release, specific salt and mucoadhesion polymer options (CMC/croscarmellose sodium), defined particle size distributions, excipient systems, and tablet dimensions.
FAQs
1) What particle-engineering element is most critical for US 9,265,720 infringement?
The requirement that zolpidem microparticles cover at least 90% of carrier exterior surfaces while mucoadhesion-promoter microparticles are also presented on the carrier exterior.
2) If a product has similar PK but uses a different sublingual format (film vs tablet), does it still infringe?
Claim 1 requires a “tablet sized for placement under a tongue” and sublingual administration. A different format can avoid the literal “tablet” and placement limitation.
3) What in vitro test is explicitly tied to dependent claims?
USP paddle dissolution using phosphate buffer pH 6.8, with ≥50% zolpidem release within 5 minutes (and optionally within 3 minutes).
4) Can changing zolpidem from hemitartrate to another salt avoid dependent claim 7?
Yes, it avoids claim 7 specifically, but claim 1 still covers “zolpidem or a pharmaceutically acceptable salt,” so architecture and PK limitations remain the main issue.
5) What competitor studies would most directly address whether claim 1 is met?
Particle localization/surface coverage studies, USP paddle release testing at 3 and 5 minutes, and tightly sampled plasma PK to establish “first measurable within 10 minutes” and the “first measurable-to-Cmax” timing window, plus sleep maintenance at 6+ hours.
References
- US Patent 9,265,720. (n.d.). Method of treating insomnia using sublingual zolpidem tablet with carrier particles and mucoadhesion-promoting agent. United States Patent Office.
